Guilin Sanjin Pharmaceutical (002275) Fundamentals 2026 — P/E 17.0x, Revenue Analysis | SniperIQ
Guilin Sanjin Pharmaceutical (002275) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥7.7B, trading at ¥13.15 on the SHZ. This SniperIQ fundamentals page covers Guilin Sanjin Pharmaceutical's valuation (P/E 17.0x, P/B 2.3x), profitability (net margin 21.5%), revenue (¥2.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Guilin Sanjin Pharmaceutical's market cap?
Guilin Sanjin Pharmaceutical (002275) has a market capitalization of approximately ¥7.7B, trading at ¥13.15 on the SHZ. Market cap moves with the live share price.
What is Guilin Sanjin Pharmaceutical's P/E ratio?
Guilin Sanjin Pharmaceutical's trailing twelve-month P/E ratio is 17.0x, with a price-to-book (P/B) of 2.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Guilin Sanjin Pharmaceutical?
Guilin Sanjin Pharmaceutical runs a net profit margin of 21.5%, a gross margin of 77.2%, and an operating margin of 27.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Guilin Sanjin Pharmaceutical generate?
Guilin Sanjin Pharmaceutical reported revenue of ¥2.0B for fiscal year 2025, with net income of ¥433M and earnings per share (EPS) of 0.74. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Guilin Sanjin Pharmaceutical pay a dividend?
Guilin Sanjin Pharmaceutical offers a trailing dividend yield of about 3.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Guilin Sanjin Pharmaceutical financially healthy?
Guilin Sanjin Pharmaceutical carries a debt-to-equity ratio of 0.13x and a current ratio of 3.97x, with a market beta of 0.21. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Guilin Sanjin Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Guilin Sanjin Pharmaceutical (002275) the key facts are: market cap ¥7.7B, P/E 17.0x, revenue ¥2.0B, 52-week range 11.91-17.38. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Guilin Sanjin Pharmaceutical's full fundamentals live
Get Guilin Sanjin Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.